Ildong Pharmaceutical Co., Ltd. (KRX: 249420)

Market Cap	343.85B
Revenue (ttm)	603.86B
Net Income (ttm)	-48.68B
Shares Out	27.93M
EPS (ttm)	-1,783.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,565
Open	12,030
Previous Close	12,150
Day's Range	12,030 - 12,450
52-Week Range	11,980 - 20,500
Beta	0.93
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About Ildong Pharmaceutical

Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1941
• Employees: 1,020
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 249420

Financial Performance

In 2023, Ildong Pharmaceutical's revenue was 600.76 billion, a decrease of -5.80% compared to the previous year's 637.71 billion. Losses were -78.93 billion, -44.25% less than in 2022.